Skip to main content
Livermore
Livermore
ZHEN

Oracle Investment Management Inc

SEC CIK
0001012622
Latest filing
Feb 18, 2026

The latest 13F from Oracle Investment Management Inc covers Q4 2025 (filed Feb 18, 2026): 17 long positions worth $152.6M. The top 10 holdings make up 98.0% of the portfolio, and the largest is GeneDx Holdings Corp. (WGS) at 75.4%. Livermore has 20 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q4 2025

Share counts compared with Q3 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
6
Est. +$4.37M
Added
4
Est. +$3.40M
Reduced
2
Est. −$3.15M
Sold out
5
Est. −$12.3M

Top 5 holdings

Share of this quarter's portfolio value

  1. WGSGeneDx Holdings Corp.
    75.4%$115.1MHistory
  2. ARDXArdelyx, Inc.
    7.2%$10.9MHistory
  3. BHVNBiohaven Ltd.
    5.7%$8.72MHistory
  4. QDELQuidelOrtho Corp
    2.2%$3.38MHistory
  5. FORAForian Inc.
    1.9%$2.90MHistory

Share of portfolio

Top 5 holdings and the other 12 positions, by share of portfolio value

  1. WGS75.4%
  2. ARDX7.2%
  3. BHVN5.7%
  4. QDEL2.2%
  5. FORA1.9%
  6. Other 12 positions7.6%

Biggest buys

New and added positions, by estimated amount bought

  1. ARDXArdelyx, Inc.
    +$2.15MAddedHistory
  2. TSHATaysha Gene Therapies, Inc.
    +$1.46MNewHistory
  3. EWTXEdgewise Therapeutics, Inc.
    +$951.5KNewHistory
  4. DAWNDay One Biopharmaceuticals, Inc.
    +$932.0KNewHistory
  5. PSNLPersonalis, Inc.
    +$874.9KAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ARDXArdelyx, Inc.
    +1.37 pp5.8% → 7.2%History
  2. TSHATaysha Gene Therapies, Inc.
    +0.96 pp0.0% → 1.0%History
  3. PSNLPersonalis, Inc.
    +0.73 pp1.0% → 1.8%History
  4. EWTXEdgewise Therapeutics, Inc.
    +0.62 pp0.0% → 0.6%History
  5. DAWNDay One Biopharmaceuticals, Inc.
    +0.61 pp0.0% → 0.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. PLTRPalantir Technologies Inc.
    −$5.38MSold outHistory
  2. CNCCentene Corp
    −$3.94MSold outHistory
  3. TDOCTeladoc Health, Inc.
    −$2.46MReducedHistory
  4. NVAXNovavax Inc
    −$2.11MSold outHistory
  5. Kraneshares Trust500767751
    −$718.6KSold out

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. PLTRPalantir Technologies Inc.
    −3.76 pp3.8% → 0.0%History
  2. CNCCentene Corp
    −2.75 pp2.7% → 0.0%History
  3. TDOCTeladoc Health, Inc.
    −2.18 pp3.8% → 1.6%History
  4. NVAXNovavax Inc
    −1.47 pp1.5% → 0.0%History
  5. Kraneshares Trust500767751
    −0.50 pp0.5% → 0.0%

Metrics

13F metrics for Q4 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$152.6M
+$9.30M (+6.5%) vs. prior quarter
Positions
17
+1 vs. prior quarter
Top 10 concentration
98.0%
Top 10 as share of value
Turnover
5.3%
Q4 2025, one quarter
Average holding period
11.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

20 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $795.6M (Q3 2021)

Q1 2021: $665.7MQ2 2021: $718.2MQ3 2021: $795.6MQ4 2021: $680.9MQ1 2022: $497.2MQ2 2022: $326.1MQ3 2022: $174.4MQ4 2022: $115.0MQ1 2023: $101.4MQ2 2023: $105.9MQ3 2023: $65.1MQ4 2023: $91.6MQ1 2024: $124.2MQ2 2024: $93.2MQ3 2024: $125.1MQ4 2024: $148.9MQ1 2025: $153.6MQ2 2025: $115.6MQ3 2025: $143.3MQ4 2025: $152.6M
Q1 2021Q4 2025
13F filings of Oracle Investment Management Inc by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q4 2025Feb 18, 202617$152.6MWGSARDXBHVNvs. Q3 2025SEC
Q3 2025Nov 19, 202516$143.3MWGSBHVNARDXvs. Q2 2025SEC
Q2 2025Aug 15, 20259$115.6MWGSBHVNARDXvs. Q1 2025SEC
Q1 2025May 15, 202511$153.6MWGSSWTXBHVNvs. Q4 2024SEC
Q4 2024Feb 14, 202513$148.9MWGSBHVNARDXvs. Q3 2024SEC
Q3 2024Nov 14, 202415$125.1MWGSBHVNPHATvs. Q2 2024SEC
Q2 2024Aug 14, 202416$93.2MWGSBHVNARDXvs. Q1 2024SEC
Q1 2024May 15, 202418$124.2MBHVNSWTXARDXvs. Q4 2023SEC
Q4 2023Feb 14, 202418$91.6MBHVNPACBQDELvs. Q3 2023SEC
Q3 2023Nov 14, 202319$65.1MBHVNQDELPACBvs. Q2 2023SEC
Q2 2023Aug 14, 202321$105.9MPACBQDELBHVNvs. Q1 2023SEC
Q1 2023May 15, 202319$101.4MPACBQDELWGSvs. Q4 2022SEC
Q4 2022Feb 14, 202317$115.0MQDELPACBAGENvs. Q3 2022SEC
Q3 2022Nov 14, 202219$174.4MBHVNQDELMRTXvs. Q2 2022SEC
Q2 2022Aug 15, 202222$326.1MBHVNQDELOPKvs. Q1 2022SEC
Q1 2022May 16, 202223$497.2MBHVNQDELOPKvs. Q4 2021SEC
Q4 2021Feb 14, 202221$680.9MBHVNQDELOPKvs. Q3 2021SEC
Q3 2021Nov 15, 202128$795.6MBHVNQDELVIRvs. Q2 2021SEC
Q2 2021Aug 16, 202125$718.2MBHVNQDELOPKvs. Q1 2021SEC
Q1 2021May 17, 202122$665.7MBHVNQDELAWHL–SEC

13D and 13G filings

Companies where Oracle Investment Management Inc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Oracle Investment Management Inc does not currently report owning 5% or more of any company.

Latest filings

1 filing on file made by Oracle Investment Management Inc or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Oracle Investment Management Inc
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
FORAForian Inc.Feb 14, 20254:08 PM ETFeinberg Larry Nand 7 others13G/A4.40%1.37M shares–Below 5%Dec 31, 2024SEC